Ilenia Segatto
Overview
Explore the profile of Ilenia Segatto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scafetta G, Rampioni Vinciguerra G, Giglio S, Faruq O, Cirombella R, Segatto I, et al.
J Exp Clin Cancer Res
. 2025 Mar;
44(1):96.
PMID: 40082972
Breast cancer ranks as the most prevalent form of cancer globally. Currently, advanced screening methods have significantly improved early detection rates. These achievements have led to more non-invasive cancer diagnoses...
2.
Pellarin I, DallAcqua A, Favero A, Segatto I, Rossi V, Crestan N, et al.
Signal Transduct Target Ther
. 2025 Jan;
10(1):11.
PMID: 39800748
Cyclin Dependent Kinases (CDKs) are closely connected to the regulation of cell cycle progression, having been first identified as the kinases able to drive cell division. In reality, the human...
3.
Nespolo A, Stefenatti L, Pellarin I, Gambelli A, Rampioni Vinciguerra G, Karimbayli J, et al.
Sci Adv
. 2024 Nov;
10(46):eadp6567.
PMID: 39536107
PARP inhibitors (PARPi) represent a game-changing treatment for patients with ovarian cancer with tumors deficient for the homologous recombination (HR) pathway treated with platinum (Pt)-based therapy. PARPi exert their cytotoxic...
4.
Segatto I, Mattevi M, Rampioni Vinciguerra G, Crestan N, Musco L, Favero A, et al.
J Pathol
. 2024 Oct;
264(4):434-447.
PMID: 39449657
Breast cancer (BC) is marked by significant genetic, morphological and clinical heterogeneity. To capture this heterogeneity and unravel the molecular mechanisms driving tumor progression and drug resistance, we established a...
5.
Rampioni Vinciguerra G, Segatto I, Carstens J, Lovisa S
Front Cell Dev Biol
. 2024 Aug;
12:1470518.
PMID: 39211387
No abstract available.
6.
Gambelli A, Nespolo A, Rampioni Vinciguerra G, Pivetta E, Pellarin I, Nicoloso M, et al.
EMBO Mol Med
. 2024 Jul;
16(8):1981.
PMID: 38997596
No abstract available.
7.
Gambelli A, Nespolo A, Rampioni Vinciguerra G, Pivetta E, Pellarin I, Nicoloso M, et al.
EMBO Mol Med
. 2024 Apr;
16(5):1162-1192.
PMID: 38658801
Platinum (PT)-resistant Epithelial Ovarian Cancer (EOC) grows as a metastatic disease, disseminating in the abdomen and pelvis. Very few options are available for PT-resistant EOC patients, and little is known...
8.
Favero A, Segatto I, Capuano A, Mattevi M, Rampioni Vinciguerra G, Musco L, et al.
NPJ Breast Cancer
. 2024 Jan;
10(1):5.
PMID: 38184660
The extracellular matrix (ECM) is an important component of the tumor microenvironment and undergoes extensive remodeling during both initiation and progression of breast cancer (BC). EMILIN1 is an ECM glycoprotein,...
9.
Tombari C, Zannini A, Bertolio R, Pedretti S, Audano M, Triboli L, et al.
Nat Commun
. 2023 Nov;
14(1):7129.
PMID: 37932286
No abstract available.
10.
Tombari C, Zannini A, Bertolio R, Pedretti S, Audano M, Triboli L, et al.
Nat Commun
. 2023 Oct;
14(1):6777.
PMID: 37880212
Reprogramming of amino acid metabolism, sustained by oncogenic signaling, is crucial for cancer cell survival under nutrient limitation. Here we discovered that missense mutant p53 oncoproteins stimulate de novo serine/glycine...